Massive Trial Tests Whether Lowering Lp(a) Can Prevent Heart Attacks and Strokes
The Lp(a)HORIZON trial enrolls 8,323 high-risk patients to find out if pelacarsen, an ASO drug, cuts major cardiovascular events.
Summary
Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting over 20% of CVD patients worldwide, yet no approved therapy exists to lower it. The Lp(a)HORIZON trial is a landmark Phase 3, randomized, double-blind, placebo-controlled study enrolling 8,323 patients with established CVD and elevated Lp(a) (≥70 mg/dL). Participants receive monthly subcutaneous injections of pelacarsen — an antisense oligonucleotide — or placebo, on top of standard care. The primary endpoint is a composite of cardiovascular death, nonfatal MI, nonfatal stroke, or urgent coronary revascularization. With a minimum 2.5-year follow-up and ~6-year total duration, results will finally determine whether pharmacologically lowering Lp(a) translates into meaningful reduction in cardiovascular morbidity and mortality.
Detailed Summary
Lipoprotein(a), or Lp(a), is a structurally unique lipoprotein comprising apolipoprotein B-100 covalently bound to apolipoprotein(a). It is independently and causally associated with atherosclerotic cardiovascular disease and calcific aortic stenosis, and its levels are largely genetically determined — meaning lifestyle changes and standard lipid-lowering drugs have minimal impact. More than 20% of the global CVD population carries elevated Lp(a), yet until now there has been no approved pharmacologic treatment and no randomized trial proving that reducing Lp(a) lowers cardiovascular risk.
Lp(a)HORIZON is designed to fill that critical gap. It is a Phase 3, multinational, randomized, double-blind, placebo-controlled trial enrolling 8,323 patients who have established CVD — defined as prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease — and Lp(a) levels ≥70 mg/dL (~149 nmol/L). Patients are randomized 1:1 to monthly subcutaneous injections of pelacarsen 80 mg, an antisense oligonucleotide targeting hepatic Lp(a) synthesis, or matching placebo, all on a background of optimized standard-of-care therapy.
The primary composite endpoint captures cardiovascular death, nonfatal MI, nonfatal stroke, or urgent coronary revascularization requiring hospitalization. The trial is event-driven, concluding when 993 confirmed primary cardiovascular events accumulate, with an anticipated total duration of approximately six years. A pre-specified subgroup analysis will also evaluate outcomes in patients with Lp(a) ≥90 mg/dL (~192 nmol/L), with multiplicity control built into the statistical framework.
If successful, Lp(a)HORIZON could validate Lp(a) as a major actionable cardiovascular risk target and establish pelacarsen as the first approved Lp(a)-lowering therapy — reshaping preventive cardiology for millions.
Caveats include the fact that this is a trial design paper only; no efficacy or safety outcomes are yet available. Results remain years away, and the trial's applicability to lower Lp(a) thresholds or primary prevention populations is unknown.
Key Findings
- Lp(a)HORIZON is the first Phase 3 RCT powered to test whether Lp(a) lowering reduces MACE in high-risk CVD patients.
- Pelacarsen is an antisense oligonucleotide given monthly via subcutaneous injection targeting hepatic Lp(a) production.
- 8,323 patients with Lp(a) ≥70 mg/dL and established CVD enrolled across multiple countries.
- Primary endpoint: composite of CV death, nonfatal MI, nonfatal stroke, or urgent coronary revascularization.
- Trial is event-driven (993 events required) with ~6-year anticipated duration and a pre-specified ≥90 mg/dL subgroup.
Methodology
Phase 3, randomized, double-blind, placebo-controlled, parallel-group multinational trial (NCT04023552) with 1:1 randomization to pelacarsen 80 mg SQ monthly vs. placebo. Event-driven design requiring 993 CEC-confirmed primary CV events; minimum 2.5-year follow-up with ~6-year total duration. Multiplicity control allows co-primary testing in the overall population and the Lp(a) ≥90 mg/dL subgroup.
Study Limitations
This publication describes only trial design and rationale — no efficacy, safety, or biomarker outcome data are available yet. The trial exclusively enrolls patients with established CVD and high Lp(a), limiting generalizability to primary prevention or moderate Lp(a) elevation. Results are not expected for several years given the event-driven design and ~6-year duration.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.